Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of “Stalking Horse” Agreement to Facilitate Sale
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE, Dec. 19, 2023 /PRNewswire/ — Impel Pharmaceuticals Inc. (OTCQX: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today … Read more